Log in
Enquire now
‌

PTC299 for Treatment of Advanced Cancer

OverviewStructured DataIssuesContributors

Contents

Study summaryTimelineTable: Further ResourcesReferences
clinicaltrials.gov/study/NCT00704821
Is a
‌
Clinical study
1

Clinical Study attributes

NCT Number
NCT007048211
Trial Recruitment Size
761
Trial Sponsor
PTC Therapeutics
PTC Therapeutics
1
Clinical Trial Start Date
July 3, 2008
1
Primary Completion Date
February 24, 2012
1
Study Completion Date
February 24, 2012
1
Clinical Trial Study Type
Interventional1
Interventional Trial Purpose
Treatment1
Intervention Type
Drug1
Intervention Name
PTC2991
Docetaxel1
Interventional Trial Phase
Phase 11
Official Name
A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer1
Last Updated
May 10, 2019
1
Allocation Type
Non-Randomized1
Intervention Model
Parallel Assignment1
Masking Type
None (Open Label)1
Study summary

Formation of new blood vessels (angiogenesis) is important for tumor growth in advanced cancer. It is known that tumors make a protein called vascular endothelial growth factor (VEGF). VEGF stimulates the formation of blood vessels that supply the tumor with nutrients and oxygen. PTC299 is an oral investigational new drug that has been shown to decrease production of VEGF in animal models of human cancer. In these animal models, oral PTC299 administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood vessel numbers in the tumor, and significantly slows or halts tumor growth. When given in combination with the chemotherapeutic drug, docetaxel, PTC299 increases the antitumor activity over use of docetaxel alone. Safety studies in research animals indicate good tolerability at doses and drug levels that are higher than those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be active in animal models of human cancer. This Phase 1b study is designed to test the hypothesis that PTC299 will be tolerable and will show evidence of anti-VEGF and antitumor activity when administered orally to participants with cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like PTC299 for Treatment of Advanced Cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.